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allogenic bone mallow transplantation (BMT) for acute myeloid leukemia is presented. The
patient received chemotherapy and total body irradiation of a total dose of 12 Gy in a condi-
tioning regimen. He was affected with chronic graft-versus-host disease after BMT, but had
not complained of symptom in the oral cavity. Oral examination showed an ulcerative mass
with induration at the right lateral border of the tongue. The mass was diagnosed as a squamous
cell carcinoma by biopsy. The tumour was surgically removed. There was no evidence of recur-
rence or metastasis 9 months after surgery. The necessity of long-term follow-up of the oral
cavity in recipients undergoing BMT is emphasized.c 2006 Elsevier Ltd. All rights reserved.
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dIntroduction
Bone marrow transplantation (BMT) has become an essential
part of the treatment for many cases of malignant and non-
malignant hematological disorders, but it is still associated
with a wide range of complications. Among the complica-
tions following BMT, graft versus host disease (GVHD) is
the most important and frequent. The development of sec-
ondary malignancies is also reported as one of the complica-
tions, and these secondary malignancies are classified into741-9409/$ - see front matter c 2006 Elsevier Ltd. All rights reserved
oi:10.1016/j.ooe.2006.04.001
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E-mail address: hyoshida@md.tsukuba.ac.jp (H. Yoshida).three categories: hematologic malignancies, lymphoprolif-
erative disorders, and solid tumours. The first two are rela-
tively frequent and usually occur soon after transplant,
whereas the last is less common and the risk seems to
increase over time.1–4 Overall, the risk of incidence of
secondary solid tumour in patients undergoing BMT is
reported to be two to three times greater than in the gen-
eral population.5 About one-third of all secondary solid
tumours are skin and mucosal cancers, with squamous cell
carcinoma (SCC) representing 50% of these cases.1,3–5 How-
ever, to our knowledge, only 13 cases of oral squamous cell
carcinoma following BMT are reported.3,6–14 We present a
new case of tongue SCC developing 7 years and 7 months
after BMT..
Figure 2 T2-weighted MRI sequence showing a mass (arrow)
with high intensity at the right lateral border of the tongue.
Figure 3 Histologic features of the biopsy specimen showing
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A 33-year-old man was referred to the Division of Oral and
Maxillofacial Surgery, University of Tsukuba Hospital, from
the Department of Hematology of the same hospital in June
2005, complaining of contact pain of the tongue. The pa-
tient had had acute myeloid leukemia diagnosed in Decem-
ber 1996, when he was 26 years old, and he underwent a
BMT from his HLA-identical mother in November 1997, fol-
lowing a conditioning regimen that consisted of chemother-
apy (2 days of cyclophosphamide at 3600 mg/day and 2 days
of etoposide at 1200 mg/day), and total body irradiation
(TBI; total dose of 12 Gy with multiple fractions). After
the BMT, the recipient was treated with cyclosporin A at
5 mg/kg for 7 months as immunosuppressive therapy. He
was affected with acute graft-versus-host disease (GVHD)
in the skin and liver after the BMT, which subsequently be-
came chronic GVHD, which eventually resolved 10 months
after BMT. The patient had no oral symptoms during the
time he had acute and chronic GVHD, but it was unclear
from his records whether or not oral pathologies were pres-
ent during this time. The patient has received neither
immunosuppressive drugs nor medications after the comple-
tion of the administration of cyclosporine. He had aban-
doned smoking and alcohol consumption with 5 years
duration before the BMT.
Oral examination showed an ulcerative mass with indura-
tion, measuring 21 · 18 mm, at the right lateral border of
the tongue (Fig. 1). Lichen planus-like lesions were not ob-
served in the oral or perioral tissues, and his oral hygiene
condition was good and well-maintained. There was no clin-
ical lymphadenopathy suspected of being metastasis in the
neck. T2-weighted magnetic resonance images depicted a
well-demarcated mass with high intensity at the right edge
of the tongue (Fig. 2).
A biopsy specimen revealed keratinization and cordlike
clusters of alveolar tumour cells infiltrating the muscular
layers, indicating a diagnosis of well-differentiated SCC
(Fig. 3). The patient underwent partial glossectomy, and
skin grafting for the defect in the resected tongue under
general anesthesia. The surgical margins of the excised
specimen were histologically free of tumour cells. The post-
operative course was uneventful, and as of his most recentFigure 1 Clinical appearance showing an ulcerative mass
(arrow) on the tight lateral border of the tongue.
keratinization and cordlike clusters of alveolar tumour cells
infiltrating muscular layers (H & E staining, ·100).follow-up examination, 9 months after the surgery, there
has been no evidence of recurrence or distant metastasis.Discussion
The improvement in the survival rate of BMT patients has re-
sulted in an increased incidence of long-tem complications,
including the development of secondary malignant solid tu-
mours.5 One of the most common sites of solid cancers in
these recipients is reported to be an oral cavity,1,5 and
many of these oral cancers has been histologically diag-
nosed as SCC. Although oral SCC is considered to be frequent
as secondary solid tumour in BMT recipients, there were
only 13 reported cases of oral SCC following BMT in the
Table 1 Previously reported cases of oral SCC after BMT
Authors Age of
diagnosis
Sex Location Primary
disease
Intervala
(year)
Oral
GVHD
TNM
classification
Treatment
Bradford et al.6 29 F Tongue FA 10 + T4N0M0 R+C+S
Lishner et al.7 41 M Buccal mucosa AA 6 + T4N0M0 S
Socie et al.8 29 M Oral cavity AA 5 + NS S
12 M Tongue FA 6 – NS S
Flowers et al.9 30 F Tongue FA 10 + NS NS
24 F Tongue FA 10 + NS NS
Millen et al.10 18 F Buccal mucosa FA 9 + T3N1M0 S
Otsubo et al.3 20 F Gingiva AA 8 + T3N0M0 S
Kawabe et al.11 53 F Floor of the mouth CML 6 + T1N0M0 S
Zhang et al.12 35 M Tongue CML 8 + T3N0M0 S+R
Abdelsayed et al.13 14 M Tongue ALL 8 – T2N0M0 S
Noji et al.14 18 M Tongue ALL 11 + T2N0M0 S
The present case 4 33 M Tongue AML 7 – T2N0M0 S
FA, Fanconi’s anemia; AA, aplastic anemia; ALL, acute lymphocytic leukemia; AML, acute myeloid leukemia; CML, chronic myeloid
leukemia; NS, not stated; S, surgery; R, radiation; C, chemotherapy.
a Interval between transplantation and diagnosis of SCC.
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six females, with an age range from 12 to 53 years, and a
mean age of 28.2 years. The tumours arose predominately
in the tongue and infrequently in the buccal mucosa, gin-
giva, and floor of the mouth. The duration between BMT
and the detection of oral cancer ranged from 5 to 11 years,
with a mean of 7.9 years. Surgeries were performed for the
oral cancers in all but two cases, for which the treatment
modality was not reported. Ten of 13 reported cases had
chronic GVHD (Table 1). As described by Demarosi et al.,
this small sample series suggests that patients affected with
oral secondary cancer after BMT tend to be male and are
younger than oral cancer patients in the general population,
where the tumour is predominant in male and uncommon
among young adults.4
Several potential risk factors for secondary solid cancer
following BMT have been previously noted. The cytotoxic
therapy of the conditioning regimen, consisting of chemo-
therapeutic agents and irradiation, has been suggested as
the primary risk factor, because this regimen could induce
gene mutations and enhance the risk of malignant transfor-
mation of cells.4,15,16 Chronic GVHD may be predisposing
factor, because oral SCC was reported to develop at the site
of a previous chronic GVHD lesion in many of the reported
cases. Stimulation of the oral mucosa by GVHD may there-
fore be associated with the development of can-
cers.1,2,4,5,10,17 Prolonged use of immunosuppressive drugs
allows the malignant transformation of cells,3,4,18 as well
as the growth of genetically abnormal cells which is nor-
mally controlled by the immune system, so the post-BMT
treatment may be a risk factor. A significant relationship
was found between patient age at the time of BMT and
the risk of solid cancer: there is an increased risk of devel-
oping secondary tumours after BMT in patients under 30
years old,1,4 so age is considered as a significant risk factor.
The fact that 8 of the 13 reported cases were in patients
under 30 years old supports this hypothesis. As other risk
factors, human papilloma virus infection, a primary diagno-
sis of hematological disorders, and type of transplant have
been described.4The increased use of BMT treatment and better survival
of the recipients after BMT are anticipated in future. Oral
secondary cancers have the potential to occur in BMT recip-
ients many years after BMT, so the necessity of long-term
follow-up of the patients is emphasized to detect cancers
early. In addition, BMT patients should be informed of high
potential cancer risk and encouraged to adopt a preventive
life style, avoiding risk factors such as smoking, alcohol con-
sumption, and poor oral hygiene.References
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